Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 6/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038121 | 0.83 | OGA (0.52) | OGAHRH3 | |
| SCHEMBL20037465 | 0.83 | OGA (0.52) | OGAHRH3HTR3EHTR3BHTR3A | |
| SCHEMBL22692189 | 0.81 | OGA (0.57) | OGAHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL11527143 | 0.80 | HTR3A (0.56) | OGAHRH3KDM4EALDH1A1HTR3E | |
| SCHEMBL18291486 | 0.79 | HRH3 (0.50) | OGAHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL20045994 | 0.79 | HRH3 (0.50) | OGAHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL278668 | 0.79 | CYP1A2 (0.61) | OGAHRH3ALDH1A1MAPTCYP1A2 | |
| SCHEMBL20038154 | 0.79 | OGA (0.48) | OGAHRH3KDM4EALDH1A1HTR3E | |
| SCHEMBL25106007 | 0.77 | CYP1A2 (0.57) | OGAALDH1A1MAPTCYP1A2 | |
| SCHEMBL20249325 | 0.77 | HRH3 (0.48) | OGAHRH3KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | OGA 4627/4885HRH3 2304/4885KDM4E 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.